A clinical trial of avapritinib versus regorafenib (Stivarga®) for people with advanced GIST that has progressed following first-line treatment with imatinib (Gleevec®) and one or two additional treatment regimens (third-line or fourth-line GIST).
As a Center for the Fight Against Cancer (CLCC) , the Paoli-Calmettes Institute is qualified as a Private Health Establishment (ESPIC) by the Public Health Code and is charged with a mission of public hospital service in oncology: cancer prevention and screening, cancer research on all diagnostic and therapeutic aspects of cancer pathology, care of patients from a diagnostic and clinical point of view over their entire course and continuing education and training in oncology.
Marseille, France Clinical Trial Location
232 Boulevard de Sainte-Marguerite,
13009 Marseille, France